Non Hodgkin’s Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Non Hodgkin’s lymphoma markets reached a value of US$ 4.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7.4 Billion by 2034, exhibiting a growth rate (CAGR) of 5.71% during 2024-2034.
The Non Hodgkin’s lymphoma market has been comprehensively analyzed in IMARC’s new report titled “Non Hodgkin’s Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Non Hodgkin’s lymphoma (NHL) is a type of cancer that affects the lymphatic system, which is part of the body's immune system. It is characterized by the uncontrolled growth of lymphocytes that may lead to the formation of tumors in the lymph nodes, bone marrow, spleen, and liver. There are several subtypes of NHL, which can be broadly categorized into two main groups: B-cell NHLs and T-cell NHLs. The symptoms of the disease can vary depending on the type and stage of cancer, as well as the location and size of the tumors. Some of the common symptoms that are indicative of NHL are swollen lymph nodes, fever, night sweats, fatigue, weight loss, persistent itching, abdominal pain or swelling, etc. The diagnosis typically involves several tests and procedures, including blood tests, biopsy, imaging tests, flow cytometry, etc. Additionally, numerous imaging tests, such as X-rays, CT scans, MRI scans, PET scans, etc., can assist in identifying the location, size, and extent of the tumors as well as the health of surrounding tissues and organs. In some cases, a bone marrow biopsy may be required to determine the spread of cancer in the bone marrow.
The rising incidences of several types of blood cancer and the inflating unmet need for novel therapies with improved safety profiles are primarily driving the global Non Hodgkin’s lymphoma market. In addition to this, the escalating utilization of molecular diagnostics for diagnosing NHL since it provides detailed information about the specific subtype of NHL, which is important for determining the best course of treatment, is further propelling the market growth. Moreover, the widespread adoption of targeted therapy, that uses drugs to target specific genetic mutations in cancer cells to treat certain subtypes of NHL, such as mantle cell lymphoma, is creating a positive outlook for the market. Apart from this, the emerging popularity of stem cell transplantation for treating NHL patients who have a relapsed or refractory form of the disease is also acting as a significant growth-inducing factor. Additionally, the ongoing advancements in biopsy techniques, including the introduction of fine-needle aspiration and core needle biopsy, which make it easier for healthcare providers to obtain tissue samples for diagnosis, are further bolstering the market growth. Besides this, the increasing adoption of innovative immune checkpoint inhibitors since they significantly improve progression-free survival in patients with NHL as compared to other treatments is expected to drive the global Non Hodgkin’s lymphoma market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the Non Hodgkin’s lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Non Hodgkin’s lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Non Hodgkin’s lymphoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Non Hodgkin’s lymphoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Non Hodgkin’s lymphoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Non Hodgkin’s lymphoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Non Hodgkin’s lymphoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Non Hodgkin’s lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Non Hodgkin’s lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Non Hodgkin’s lymphoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of Non Hodgkin’s lymphoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Non Hodgkin’s lymphoma by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of Non Hodgkin’s lymphoma by type across the seven major markets?
How many patients are diagnosed (2018-2034) with Non Hodgkin’s lymphoma across the seven major markets?
What is the size of the Non Hodgkin’s lymphoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Non Hodgkin’s lymphoma?
What will be the growth rate of patients across the seven major markets?
Non Hodgkin’s Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Non Hodgkin’s lymphoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Non Hodgkin’s lymphoma market?
What are the key regulatory events related to the Non Hodgkin’s lymphoma market?
What is the structure of clinical trial landscape by status related to the Non Hodgkin’s lymphoma market?
What is the structure of clinical trial landscape by phase related to the Non Hodgkin’s lymphoma market?
What is the structure of clinical trial landscape by route of administration related to the Non Hodgkin’s lymphoma market?
The Non Hodgkin’s lymphoma market has been comprehensively analyzed in IMARC’s new report titled “Non Hodgkin’s Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Non Hodgkin’s lymphoma (NHL) is a type of cancer that affects the lymphatic system, which is part of the body's immune system. It is characterized by the uncontrolled growth of lymphocytes that may lead to the formation of tumors in the lymph nodes, bone marrow, spleen, and liver. There are several subtypes of NHL, which can be broadly categorized into two main groups: B-cell NHLs and T-cell NHLs. The symptoms of the disease can vary depending on the type and stage of cancer, as well as the location and size of the tumors. Some of the common symptoms that are indicative of NHL are swollen lymph nodes, fever, night sweats, fatigue, weight loss, persistent itching, abdominal pain or swelling, etc. The diagnosis typically involves several tests and procedures, including blood tests, biopsy, imaging tests, flow cytometry, etc. Additionally, numerous imaging tests, such as X-rays, CT scans, MRI scans, PET scans, etc., can assist in identifying the location, size, and extent of the tumors as well as the health of surrounding tissues and organs. In some cases, a bone marrow biopsy may be required to determine the spread of cancer in the bone marrow.
The rising incidences of several types of blood cancer and the inflating unmet need for novel therapies with improved safety profiles are primarily driving the global Non Hodgkin’s lymphoma market. In addition to this, the escalating utilization of molecular diagnostics for diagnosing NHL since it provides detailed information about the specific subtype of NHL, which is important for determining the best course of treatment, is further propelling the market growth. Moreover, the widespread adoption of targeted therapy, that uses drugs to target specific genetic mutations in cancer cells to treat certain subtypes of NHL, such as mantle cell lymphoma, is creating a positive outlook for the market. Apart from this, the emerging popularity of stem cell transplantation for treating NHL patients who have a relapsed or refractory form of the disease is also acting as a significant growth-inducing factor. Additionally, the ongoing advancements in biopsy techniques, including the introduction of fine-needle aspiration and core needle biopsy, which make it easier for healthcare providers to obtain tissue samples for diagnosis, are further bolstering the market growth. Besides this, the increasing adoption of innovative immune checkpoint inhibitors since they significantly improve progression-free survival in patients with NHL as compared to other treatments is expected to drive the global Non Hodgkin’s lymphoma market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the Non Hodgkin’s lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Non Hodgkin’s lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Non Hodgkin’s lymphoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Non Hodgkin’s lymphoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Non Hodgkin’s lymphoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Non Hodgkin’s lymphoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Non Hodgkin’s lymphoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Non Hodgkin’s lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Non Hodgkin’s lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Non Hodgkin’s lymphoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of Non Hodgkin’s lymphoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Non Hodgkin’s lymphoma by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of Non Hodgkin’s lymphoma by type across the seven major markets?
How many patients are diagnosed (2018-2034) with Non Hodgkin’s lymphoma across the seven major markets?
What is the size of the Non Hodgkin’s lymphoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Non Hodgkin’s lymphoma?
What will be the growth rate of patients across the seven major markets?
Non Hodgkin’s Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Non Hodgkin’s lymphoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Non Hodgkin’s lymphoma market?
What are the key regulatory events related to the Non Hodgkin’s lymphoma market?
What is the structure of clinical trial landscape by status related to the Non Hodgkin’s lymphoma market?
What is the structure of clinical trial landscape by phase related to the Non Hodgkin’s lymphoma market?
What is the structure of clinical trial landscape by route of administration related to the Non Hodgkin’s lymphoma market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NON HODGKIN’S LYMPHOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NON HODGKIN’S LYMPHOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NON HODGKIN’S LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 NON HODGKIN’S LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NON HODGKIN’S LYMPHOMA - UNMET NEEDS
10 NON HODGKIN’S LYMPHOMA - KEY ENDPOINTS OF TREATMENT
11 NON HODGKIN’S LYMPHOMA - MARKETED PRODUCTS
11.1 List of Non Hodgkin’s Lymphoma Marketed Drugs Across the Top 7 Markets
11.1.1 Zevalin (Ibritumomab tiuxetan) - Acrotech Biopharma /Biogen
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Zydelig (Idelalisib) - Gilead Sciences
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Rituxan (Rituximab) - Biogen Idec/Genentech
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Mozobil (Plerixafor) - Sanofi
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Treanda (Bendamustine) - Astellas Pharma GmbH
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 NON HODGKIN’S LYMPHOMA - PIPELINE DRUGS
12.1 List of Non Hodgkin’s Lymphoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Epcoritamab - Genmab
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Betalutin - Lutetium-177 lilotomab satetraxetan
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Copanlisib - Bayer HealthCare Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 NKTR255- Nektar Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 TAK-981 - Takeda Oncology
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. NON HODGKIN’S LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. NON HODGKIN’S LYMPHOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NON HODGKIN’S LYMPHOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Non Hodgkin’s Lymphoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Non Hodgkin’s Lymphoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Non Hodgkin’s Lymphoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Non Hodgkin’s Lymphoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Non Hodgkin’s Lymphoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Non Hodgkin’s Lymphoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Non Hodgkin’s Lymphoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Non Hodgkin’s Lymphoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Non Hodgkin’s Lymphoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Non Hodgkin’s Lymphoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Non Hodgkin’s Lymphoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Non Hodgkin’s Lymphoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Non Hodgkin’s Lymphoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Non Hodgkin’s Lymphoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Non Hodgkin’s Lymphoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Non Hodgkin’s Lymphoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Non Hodgkin’s Lymphoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Non Hodgkin’s Lymphoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Non Hodgkin’s Lymphoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Non Hodgkin’s Lymphoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Non Hodgkin’s Lymphoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Non Hodgkin’s Lymphoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Non Hodgkin’s Lymphoma - Access and Reimbursement Overview
16 NON HODGKIN’S LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NON HODGKIN’S LYMPHOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NON HODGKIN’S LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NON HODGKIN’S LYMPHOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NON HODGKIN’S LYMPHOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NON HODGKIN’S LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 NON HODGKIN’S LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NON HODGKIN’S LYMPHOMA - UNMET NEEDS
10 NON HODGKIN’S LYMPHOMA - KEY ENDPOINTS OF TREATMENT
11 NON HODGKIN’S LYMPHOMA - MARKETED PRODUCTS
11.1 List of Non Hodgkin’s Lymphoma Marketed Drugs Across the Top 7 Markets
11.1.1 Zevalin (Ibritumomab tiuxetan) - Acrotech Biopharma /Biogen
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Zydelig (Idelalisib) - Gilead Sciences
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Rituxan (Rituximab) - Biogen Idec/Genentech
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Mozobil (Plerixafor) - Sanofi
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Treanda (Bendamustine) - Astellas Pharma GmbH
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 NON HODGKIN’S LYMPHOMA - PIPELINE DRUGS
12.1 List of Non Hodgkin’s Lymphoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Epcoritamab - Genmab
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Betalutin - Lutetium-177 lilotomab satetraxetan
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Copanlisib - Bayer HealthCare Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 NKTR255- Nektar Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 TAK-981 - Takeda Oncology
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. NON HODGKIN’S LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. NON HODGKIN’S LYMPHOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NON HODGKIN’S LYMPHOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Non Hodgkin’s Lymphoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Non Hodgkin’s Lymphoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Non Hodgkin’s Lymphoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Non Hodgkin’s Lymphoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Non Hodgkin’s Lymphoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Non Hodgkin’s Lymphoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Non Hodgkin’s Lymphoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Non Hodgkin’s Lymphoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Non Hodgkin’s Lymphoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Non Hodgkin’s Lymphoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Non Hodgkin’s Lymphoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Non Hodgkin’s Lymphoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Non Hodgkin’s Lymphoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Non Hodgkin’s Lymphoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Non Hodgkin’s Lymphoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Non Hodgkin’s Lymphoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Non Hodgkin’s Lymphoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Non Hodgkin’s Lymphoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Non Hodgkin’s Lymphoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Non Hodgkin’s Lymphoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Non Hodgkin’s Lymphoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Non Hodgkin’s Lymphoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Non Hodgkin’s Lymphoma - Access and Reimbursement Overview
16 NON HODGKIN’S LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NON HODGKIN’S LYMPHOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NON HODGKIN’S LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
